Lecope-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic rhinitis and chronic asthma. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic conditions. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), mitigating inflammation, bronchoconstriction, and mucus production in the airways. The synergistic action of these agents provides comprehensive relief by targeting multiple pathways involved in allergic and asthmatic responses. Lecope-M is typically prescribed for patients experiencing seasonal or perennial allergic rhinitis and as an adjunct therapy in the prophylaxis and chronic treatment of asthma to improve pulmonary function and reduce exacerbations. The tablet is administered orally, usually once daily, with or without food, as directed by a healthcare professional. Common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal discomfort. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with hypersensitivity to either component. Lecope-M offers an effective therapeutic option for patients requiring combined antihistaminic and leukotriene receptor antagonist therapy.